A. Yu. Butirskiy

A. Yu. Butirskiy

Auto-generated profile, based on publicly available information

A. Yu. Butirskiy

Scientific Centre for Expert Evaluation of Medicinal Products

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Problems of Virology
Verified
Journal Article
Open access
PDF file
ABA. Yu. Butirskiy
A. Yu. Butirskiy
AMA. V. Muhacheva
A. V. Muhacheva
AMA. A. Movsesyants
A. A. Movsesyants
KSK. A. Sarkisyan
K. A. Sarkisyan
Introduction. Rabies is an infectious disease that is always fatal following the onset of clinical symptoms. The only way to prevent the cases of rabies in humans is timely carried out the rabies post-exposure prophylaxis in accordance with the recommended schedule.The aim of the study was to characterize the level of immune response in persons that received a post-exposure prophylaxis against rabies, to consider the role of the factors of the formation immune responses to rabies vaccines .Material and methods. In the laboratory of viral vaccines of the Scientific Centre for Expert Evaluation of Medicinal Products, the 48 sera of patients that received the post-exposure prophylaxis of rabies after wounds from a rabid or suspected rabid animal has been studied. The titer of virus neutralizing antibodies (VNA) to the rabies virus in the sera of the vaccinated not less than 1:64 (corresponding to a level of VNA at least 0,5 IU /ml) in the mouse neutralization test indicates the effective vaccination.Results and discussion. Our data confirm the absence of statistically significant differences in the level of VNA in the vaccinated persons that received a complete and incomplete (5 doses) course of post-exposure vaccination against rabies. Depending on the level of VNA, all patients are divided into groups with conditionally low, medium and high content of antibodies in sera.Conclusion. It has been shown that in most cases properly administered vaccination contributed to the formation of effective immune response. The lack of a protective level of BHA requires additional administration of the vaccine and analysis of the factors that influenced the ineffectiveness of vaccination. In some patients the determination of rabies virus neutralizing antibody titres is necessary.

21 September 2023 in Problems of Virology
Verified
Journal Article
Open access
PDF file
ABA S Binyatova
A S Binyatova
TYT N Yunasova
T N Yunasova
RVR A Volkova
R A Volkova
ABA Y Butirskiy
A Y Butirskiy
TIT N Ilyasova
T N Ilyasova
AMA A Movsesyants
A A Movsesyants
Introduction. Due to the increased incidence of measles in Russia and in many other regions of the world, vaccines for the measles prevention are especially in demand. Ensuring the quality of the measles vaccine for effective disease prevention is within the scope of the tasks of the state policy of our country. Objective. Evaluation of the experience of using a pharmacopoeial standard material of measles vaccine activity for measurement of the specific activity of the measles virus in vaccines with a measles component that are used in the Russian Federation for measles prevention. Materials and methods. The object of the study was the Pharmacopoeia reference material (PRM) of the activity of the live measles vaccine of series 10. The activity of PRM was analyzed when determining the specific activity of the measles, mumps-measles and combined vaccines for the prevention of measles, rubella and mumps, as well as based on the materials of the summary protocols for the production of these vaccines. Results. The titer of the measles virus in the PRM for each determination of the specific activity of the measles virus in vaccines in the Scientific Centre for Expert Evaluation of Medicinal Products in 20212022, as well as according to the summary production protocols, was within the boundaries of the certified value (4.63 0.5) lgTCD50/0.5 ml, and the test results met the acceptance criteria in accordance with the requirements of regulatory documentation. During the observation period, the average value of the PRM titer (4.61 lgTCD50/0.5 ml) practically did not differ compared to the average value of the certified characteristics of the PRM, the standard deviation of the mean value of the measles virus titer in the PRM did not exceed 0.15 lgTCD50, which indicated the stability of the analytical work at the enterprise and in IC. Conclusion. The data obtained indicate the stable activity of PRM, the correctness of the determination of the measles virus titer in the vaccination dose of the vaccine, and the validity of the method for monitoring the specific activity of the measles virus in vaccines.

4 August 2026 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
NIN. L. Ivanutina
N. L. Ivanutina
SDS. I. Dovbysh
S. I. Dovbysh
RVR. A. Volkova
R. A. Volkova
AEA. A. Ekimov
A. A. Ekimov
NSN. N. Savina
N. N. Savina
ЕМЕ. Н. Морозова
Е. Н. Морозова
INTRODUCTION. In the absence of an international reference standard for the antigen and the corresponding antiserum for quantifying influenza virus hemagglutinin (HA) content by single radial immunodiffusion (SRID), as well as during pandemics or other emergencies, validated alternative methods for HA quantification are required. AIM. Optimization of the method for certifying a primary reference standard for quantification of influenza virus hemagglutinin using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by densitometric analysis of the gels. MATERIALS AND METHODS. The HA content (%) in the reference standard was determined by SDS-PAGE under reproducibility conditions (two laboratories). HA concentration (µg/mL) was calculated from the total protein content determined by the Lowry method. The SRID method was used to evaluate the accuracy of HA quantification. The CombiStats software was used for plate image processing, calculation of the squared diameters of precipitation rings, and determination of HA content in the samples. Sucrose and glycerol in the virus concentrate and the diluted virus concentrate (DVC) were quantified by high-performance liquid chromatography. RESULTS. When performing SDS-PAGE with deglycosylation, the addition of 0.072 mM 2-mercaptoethanol for sample processing eliminates the need for urea. The HA concentrations in DVC determined by SDS-PAGE using 4–12% Bis-Tris gels in Laboratory 1 (135.8 µg/mL) and 4–20% Tris-glycine gels in Laboratory 2 (135.5 µg/mL) were virtually identical; the coefficient of variation did not exceed 4% in either laboratory. The HA concentration determined by SDS-PAGE in Laboratory 1 was comparable to the SRID data (123.6 µg/mL). The content of excipients (glycerol and sucrose) in DVC did not exceed 55 µg/mL and did not affect the results of protein determination. CONCLUSIONS. Optimal SDS-PAGE conditions were established for certifying a primary liquid reference standard for quantification of influenza virus HA, yielding results comparable to those of the SRID method. The next phase of the study will involve testing the sample preparation conditions and quantification methods for all HA types (H1N1, H3N2, and B) relevant to the 2025–2026 season.

19 December 2025 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ABA. Yu. Butirskiy
A. Yu. Butirskiy
AKA. S. Korovkin
A. S. Korovkin
AMA. A. Movsesyants
A. A. Movsesyants
VMV. A. Merkulov
V. A. Merkulov
INTRODUCTION . Rabies is an invariably fatal disease having no adequate cure; in some cases it requires administration of rabies immunoglobulin combined with rabies vaccine. Given the supply constraints of rabies immunoglobulin derived from donor blood, research is underway worldwide to develop preparations based on neutralising monoclonal antibodies (mAbs), which are potentially relevant for the Russian healthcare system. AIM. This study aimed to perform a narrative review of the development, clinical trials, and post-marketing safety and efficacy studies of rabies monoclonal antibodies intended for post-exposure prophylaxis in combination with rabies vaccination. DISCUSSION . Currently, three rabies mAb drugs have been registered worldwide. Of them, two are manufactured in India (a recombinant human anti-rabies antibody; a combination drug of docaravimab and miromavimab) and one in China (ormutivimab). Preclinical studies of these drugs have confirmed their ability to neutralise the rabies virus, including wild strains. Clinical trials have established a favourable safety profile for these anti-rabies mAbs (adverse events are generally transient and self-resolving) and a lack of immune interference with administered rabies vaccines. Administration of all the above drugs did not change immune response to the complete course of anti-rabies vaccination, unlike human immunoglobulin preparations. On Day 42 (4 weeks after the last dose of rabies vaccine), virus-neutralising antibody titers reached 31.12 IU/mL for the recombinant human rabies antibody preparation and 122 IU/mL for docaravimab and miromavimab combination. Controlled clinical trials and post-registration studies of the recombinant human rabies antibody and docaravimab-miromavimab combination showed no rabies episodes in patients receiving post-exposure prophylaxis with the study drugs and the rabies vaccine. CONCLUSIONS . Anti-rabies mAb preparations are an effective and safe option for post-exposure rabies prophylaxis, confirmed by their worldwide use. Integrating these drugs into comprehensive patient care will help overcome the potential shortage of rabies immunoglobulins in the Russian Federation. When registering anti-rabies mAbs, key objectives are to assess cross-reactivity with human tissues ex vivo and confirm neutralising activity against viral isolates common in Russia and the neighbouring countries.

12 March 2025 in Problems of Virology
Verified
Journal Article
Open access
PDF file
ABA Y Butirskiy
A Y Butirskiy
EME N Morozova
E N Morozova
KSK A Sarkisyan
K A Sarkisyan
Introduction. The main quality indicator for inactivated influenza vaccines is their potency (the amount of hemagglutinin). The potency test for the influenza vaccine with the SOVIDON adjuvant is carried out in a trivalent bulk vaccine before the addition of the adjuvant. This approach has its fair share of drawbacks. The analysis of the statistical process control and stability by control charts plays an important role in the release of influenza vaccines. The aim of the study is to compare the results of hemagglutinin quanitation in the trivalent bulk vaccine and in the final lots of influenza vaccine with SOVIDON adjuvant; as well as the analysis of the potency test results to evaluate the statistical process control. Materials and methods. This study covered the inactivated influenza vaccine with the SOVIDON adjuvant. Both the trivalent bulks vaccine before the addition of the adjuvant and the final lots were investigated by single radial immunodiffusion assay. The software SIAMS Photolab was used to calculate the amount of hemagglutinin. Microsoft Excel was used to create the control charts using the data of the manufacturer. Results. The data of the study confirm the absence of statistically significant differences (p 0.05) of the content of hemagglutinin in the trivalent bulks and the final lots of the influenza vaccine. The analysis of control charts showed the presence of out-of-control signals. Conclusion. The study has shown the possibility and feasibility of the potency testing of the influenza vaccine with the SOVIDON adjuvant. The presence of out-of-control signals on the control charts is the basis for the identification of the reasons behind the changes and for the analysis of risks of the release of a defective influenza vaccine.

5 October 2026 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ABA. Yu. Butirskiy
A. Yu. Butirskiy
AKA. S. Korovkin
A. S. Korovkin
Dmitry V. GorenkovDmitry V. Gorenkov
Dmitry V. Gorenkov
VMV. A. Merkulov
V. A. Merkulov
АБА. Ю. Бутырский
А. Ю. Бутырский
ВМВ. А. Меркулов
В. А. Меркулов
INTRODUCTION. The mRNA platform technology for creating vaccines against infectious diseases was introduced into clinical practice during the COVID-19 pandemic; however, the accumulated experience of clinical use of mRNA vaccines requires systematization in relation to other infectious diseases. Therefore, summarizing data on the efficacy and safety of such mRNA vaccines in controlled clinical trials is relevant for substantiating approaches to the regulatory evaluation of immunobiological medicinal products of this class. AIM. To review the results of clinical trials of mRNA vaccines for the prevention of respiratory syncytial virus infection (RSV infection), cytomegalovirus infection (CMV infection), seasonal influenza, Zika fever, and rabies to summarize data on their efficacy and safety, identifying the limitations associated with the use of surrogate endpoints and sample size. DISCUSSION. The authors analyzed publications in PubMed, eLIBRARY.RU and records in ClinicalTrials.gov describing the results of controlled clinical trials of mRNA vaccines for the prevention of infectious diseases (excluding COVID-19) from 2016 to 2026. Clinical efficacy was confirmed only for the mRNA-1345 vaccine against RSV infection: 83.7% (for episodes with 2 symptoms) and 82.4% (for episodes with 3 symptoms); the safety profile was considered satisfactory. For mRNA vaccines against seasonal influenza, a favorable safety profile and pronounced seroconversion in the hemagglutination inhibition assay were confirmed; the humoral immunity parameters were comparable to those of licensed vaccines. The mRNA-1647 vaccine against CMV infection, after a three-dose regimen, induced a durable immune response with the activation of T-cell immunity, along with a favorable safety profile. In a study of vaccines for the prevention of Zika fever (mRNA-1325, mRNA-1893), the presence of neutralizing antibodies (in a neutralization assay) after vaccination was demonstrated in participants with different baseline flavivirus serostatus; the safety profile was considered favorable. The mRNA vaccine CV7201 against rabies induced protective titers of virus-neutralizing antibodies in 71% of study participants after intradermal administration and in 46% after intramuscular administration; the incidence of local and systemic adverse events (AEs) was high (97% and 78%, respectively). Most studies were shown to have limitations associated with the assessment of efficacy using surrogate endpoints and an insufficient sample size to detect rare adverse events. CONCLUSIONS. The results of controlled clinical trials of mRNA vaccines for the prevention of RSV and CMV infection, seasonal influenza, Zika fever, and rabies demonstrated their potential efficacy and acceptable safety profile; however, the evaluation of most products is based on surrogate endpoints and small sample sizes, which are the main limitations of the conducted studies. The findings substantiate the need for further research using endpoints (clinical efficacy, surrogate markers) and post-marketing safety monitoring (primarily for local and systemic AEs).